Progensa PCA3 assay diagnostic data

A prospective sub-analysis of 1,072 patients enrolled in the placebo arm and who were scheduled to undergo regular biopsies at 2 and 4 years in the Phase III REDUCE trial evaluating Avodart dutasteride to reduce the risk of biopsy-detectable prostate cancer showed that PCA3 scores as measured by Gen-Probe's Progensa PCA3 assay were significantly correlated with a positive prostate biopsy result and that men who had higher PCA3 scores were more likely to have prostate cancer. Specifically, prostate cancer was diagnosed in 6% of men with a PCA3 score <5 vs. 57% of men with a PCA3 score >100. Furthermore, men with elevated PCA3 scores and a negative biopsy at 2 years were twice as likely as men with lower PCA3 scores to have cancer detected through prostate biopsy at 4 years. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. ...